Aggressive lipid management in very elderly adults: Less is more

Journal of the American Geriatrics Society

Volumn 62, Issue 5, 2014, Pages 945-947

  Rich, Michael W ^a  

^a WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALISKIREN; AMIODARONE; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; CHOLESTEROL; CLOPIDOGREL; DIGOXIN; DILTIAZEM; DRONEDARONE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPNOTIC SEDATIVE AGENT; IMMUNOSUPPRESSIVE AGENT; NIFEDIPINE; PRAVASTATIN; PROTON PUMP INHIBITOR; ROSUVASTATIN; SIMVASTATIN; VERAPAMIL;

AGED; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COGNITIVE DEFECT; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; DRUG EFFECT; DYSLIPIDEMIA; GERIATRICS; HUMAN; MUSCLE WEAKNESS; MYALGIA; NOTE; PATIENT HARM; POLYPHARMACY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; SENESCENCE; UNSPECIFIED SIDE EFFECT; VERY ELDERLY;

AGE FACTORS; AGED; AGED, 80 AND OVER; ATHEROSCLEROSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOLIPIDEMIC AGENTS; LIPIDS; MORBIDITY; SURVIVAL RATE; WORLD HEALTH;

EID: 84900561469     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/jgs.12788_2     Document Type: Note

References (10)

1. Weverling-Rijnsburger AWE, Blauw GJ, Lagaay AM, et al. Total cholesterol and risk of mortality in the oldest old. Lancet 1997; 350: 1119-1123.
2. Newson RS, Felix JF, Heeringa J, et al. Association between serum cholesterol and noncardiovascular mortality in older age. J Am Geriatr Soc 2011; 59: 1779-1785.
3. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial. Lancet 2002; 360: 1623-1630.
4. Heart Protection Study Collaborate Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised trial. Lancet 2002; 360: 7-22.
5. Glynn RJ, Koenig W, Borge G, et al. Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: Exploratory analysis of a randomized trial. Ann Intern Med 2010; 152: 488-496.
6. Cohen JD, Brinton EA, Ito MK, et al. Understanding Statin use in America and Gaps in patient Education (USAGE): An internet-based survey of 10,138 current and former statin users. J Clin Lipid 2012; 6: 208-215.
7. Jukema JW, Cannon CP, de Craen AJM, et al. The controversies of statin therapy. Weighing the evidence. J Am Coll Cardiol 2012; 60: 875-881.
8. Evans MA, Golomb BA,. Statin-associated adverse cognitive effects: Survey results from 171 patients. Pharmacotherapy 2009; 29: 800-811.
9. Padala KP, Padala PR, Potter JF,. Statins: A case for drug withdrawal in patients with dementia. J Am Geriatr Soc 2010; 58: 1214-1216.
10. Golomb BA, Evans MA, Dimsdale JE, et al. Effects of statins on energy and fatigue with exertion: Results from a randomized controlled trial. Arch Intern Med 2012; 172: 1180-1182.